Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Trendlines Group ( (SG:42T) ) has issued an update.
Trendlines Group announced that its portfolio company Limaca Medical has signed an exclusive U.S. distribution agreement with a global leader in endoscopy equipment for Limaca’s Precision-GI™ automated biopsy system. The deal is expected to accelerate the nationwide clinical rollout and adoption of Precision-GI™, a motorized, EUS-guided biopsy device designed to obtain high-quality core tissue samples from pancreatic and other gastrointestinal lesions while reducing blood contamination. With existing FDA clearance, Breakthrough Device status and CMS Transitional Pass-Through payment, the partnership strengthens Limaca’s commercial positioning in GI cancer diagnostics and underscores Trendlines’ strategy of advancing innovative medtech assets that can improve diagnostic accuracy and access for patients with life‑threatening cancers.
The most recent analyst rating on (SG:42T) stock is a Hold with a S$0.08 price target. To see the full list of analyst forecasts on Trendlines Group stock, see the SG:42T Stock Forecast page.
More about Trendlines Group
The Trendlines Group Ltd. is an investment group focused on agrifood and medtech innovation, building and backing early-stage technology companies. Among its portfolio is Limaca Medical, a commercial-stage medtech firm founded and incubated by Trendlines that develops automated endoscopic biopsy solutions for gastrointestinal cancer diagnosis, including its flagship Precision-GI™ system.
Average Trading Volume: 10,877,596
Technical Sentiment Signal: Hold
Current Market Cap: S$101.5M
Find detailed analytics on 42T stock on TipRanks’ Stock Analysis page.